Skip to search formSkip to main contentSkip to account menu

SR 16388

Known as: SR-16388, SR16388 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
SYNERGISTIC ANT-CANCERACTIVITY OF SR16388 WITH ANT-MITOTC DRUGS CROSS-REFERENCE TO RELATED APPLICATIONS
  • 2017
  • Corpus ID: 55993984
(54) SYNERGISTIC ANTI-CANCERACTIVITY OF Publication Classification SR16388 WITH ANT-MITOTC DRUGS (51) Int. Cl. (71) Applicant… 
2011
2011
Abstract 3532: Antitumor activity of SR16388 on multiple myeloma targets factors needed for adaptation to bone marrow microenvironment
Multiple myeloma (MM) is a B-cell malignancy that is characterized by accumulation of clonal plasma cells in the bone marrow. The… 
2010
2010
Abstract 1569: Antitumor activity of SR16388 against human multiple myeloma in vitro and in vivo
Multiple myeloma (MM) is the cancer of plasma cells that derive from a clonal disorder of terminally differentiated B cells in… 
2006
2006
SR16388 inhibits non-small cell lung tumor growth and angiogenesis
3820 We had previously determined that the steroidal antitumor agent, SR16388, inhibited matrix development and reduced… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)